In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amicus Therapeutics Inc.

www.amicusrx.com

Latest From Amicus Therapeutics Inc.

US Pharma Firms Not In Post-Brexit Trade Talks

A UK TV program revealed secret meetings between drug makers and British civil servants but for its part, the American Pharmaceutical Group says it has had no discussions on any future US/UK trade deal.
United Kingdom Reimbursement

Asia Executives On The Move: Senior Changes At Biogen, Amicus, PhRMA In Japan, Ascletis and Lupin

The coming of autumn ushers in a flurry of executive changes. Biogen has a new R&D head for Japan while Amicus Japan has a  new president, and other executive changes take place at Ascletis, Lupin and industry trade groups PhRMA and IPA.
Appointments Japan

Novartis Swaps Two AveXis Executives For One Following Zolgensma Data Manipulation

The big pharma could not confirm whether AveXis co-founder and CSO Brian Kaspar and his brother, SVP of R&D Allan Kaspar, were fired. Instead, Novartis noted that the withholding of preclinical safety data for Zolgensma was limited to the action of a few employees. NIBR preclinical safety chief takes key role at AveXis

Leadership Gene Therapy

Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire

Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amicus Therapeutics Inc.
  • Senior Management
  • John F Crowley, Chmn. & CEO
    Daphne Quimi, CFO
    Jay A Barth, MD, CMO
    Bradley L Campbell, Pres. & COO
    Hung Do, PhD, CSO
  • Contact Info
  • Amicus Therapeutics Inc.
    Phone: (609) 662-2000
    1 Cedar Brook Dr.
    Cranbury, NJ 08512
    USA
UsernamePublicRestriction

Register